The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
Open accessAbstract
PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance status 0-2; and adequate renal, hepatic, and marrow function. Prior radiotherapy and/or hormonal therapy were permitted, but chemotherapy, including radiosensitization, was not. Patients were treated with doxorubicin 45 mg/m 2 and cisplatin 50 mg/m 2 (day 1), followed by paclitaxel 160 mg/m 2 (day 2) with granulocyte colony-stimulating factor or paclitaxel 175 mg/m 2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles. The primary endpoint was overall survival (OS; modified intention to treat). Progression-free survival (PFS), health-related quality of life (HRQoL), and toxicity were secondary endpoints. RESULTS: From 2003 to 2009, 1,381 women were enrolled. Noninferiority of TC to TAP was concluded for OS (median, 37 v 41 months, respectively; hazard ratio [HR], 1.002; 90% CI, 0.9 to 1.12), and PFS (median, 13 v 14 months; HR, 1.032; 90% CI, 0.93 to 1.15). Neutropenic fever was reported in 7% of patients receiving TAP and 6% of those receiving TC. Grade > 2 sensory neuropathy was recorded in 26% of patients receiving TAP and 20% receiving TC ( P = .40). More grade ≥ 3 thrombocytopenia (23% v 12%), vomiting (7% v 4%), diarrhea (6% v 2%), and metabolic (14% v 8%) toxicities were reported with TAP. Neutropenia (52% v 80%) was more common with TC. Small HRQoL differences favored TC. CONCLUSION: With demonstrated noninferiority to TAP, TC is the global first-line standard for advanced endometrial cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Self-citationSample-Size Formula for the Proportional-Hazards Regression Model
Schoenfeld, D. A. (1983) · Biometrics · doi:10.2307/2531021 · Cited by 1,096
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7617 · Cited by 872
Self-citationFleming, G. F., Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., & Burks, R. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.184 · Cited by 565
Self-citationThigpen, J. T., Brady, M. F., Homesley, H. D., Malfetano, J., DuBeshter, B., Burger, R. A., & Liao, S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.088 · Cited by 390
Design and analysis of group sequential tests based on the type I error spending rate function
KIM, K., & DEMETS, D. L. (1987) · Biometrika · doi:10.1093/biomet/74.1.149 · Cited by 295
Hoskins, P. J., Swenerton, K. D., Pike, J. A., Wong, F., Lim, P., Acquino-Parsons, C., & Lee, N. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4048 · Cited by 275
Miller, D., Filiaci, V., Fleming, G., Mannel, R., Cohn, D., Matsumoto, T., Tewari, K., DiSilvestro, P., Pearl, M., & Zaino, R. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.034 · Cited by 255
Self-citationFleming, G. F., Filiaci, V. L., Bentley, R. C., Herzog, T., Sorosky, J., Vaccarello, L., & Gallion, H. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh316 · Cited by 202
Self-citationAapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg112 · Cited by 197
Aghajanian, C. A., Filiaci, V. L., Dizon, D. S., Carlson, J. W., Powell, M. A., Secord, A. A., Tewari, K. S., Bender, D., O’Malley, D. M., Stuckey, A. R., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.018 · Cited by 146
Self-citationGallion, H. H., Brunetto, V. L., Cibull, M. L., Lentz, S. S., Reid, G. C., Soper, J. T., Burger, R. A., & Andersen, W. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.083 · Cited by 118
New therapies for advanced, recurrent, and metastatic endometrial cancers
Makker, V., Green, A. K., Wenham, R. M., Mutch, D. G., Davidson, B. A., & Miller, D. S. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0056-7 · Cited by 111
Self-citationPast, present, and future of hormonal therapy in recurrent endometrial cancer
Leslie, K. K., Thiel, K. W., & Carlson, M. J. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s40942 · Cited by 90
Cited by
Crosbie, E. J., Kitson, S. J., McAlpine, J. N., Mukhopadhyay, A., Powell, M. E., & Singh, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00323-3 · Cited by 1,333
Self-citationDostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2216334 · Cited by 862
Self-citationPembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Eskander, R. N., Sill, M. W., Beffa, L., Moore, R. G., Hope, J. M., Musa, F. B., Mannel, R., Shahin, M. S., Cantuaria, G. H., Girda, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302312 · Cited by 758
Self-citationMakker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Lu, K. H., & Broaddus, R. R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1514010 · Cited by 663
Metadata
- Authors
- Miller, D. S., Filiaci, V. L., Mannel, R. S., Cohn, D. E., Matsumoto, T., Tewari, K. S., DiSilvestro, P., Pearl, M. L., Argenta, P. A., Powell, M. A., Zweizig, S. L., Warshal, D. P., Hanjani, P., Carney, M. E., Huang, H., Cella, D., Zaino, R., & Fleming, G. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-11-20
- Volume
- 38
- Issue
- 33
- Pages
- 3841-3850
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3093220519
- Cited by
- 351
- References
- 15
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.